What is Arima Genomics?
Arima Genomics is a biotechnology innovator specializing in 3D genomics, a field that maps the spatial architecture of DNA within the cell nucleus. By offering advanced technologies that preserve and present the structural organization of the genome, the company enables scientists to decode complex biological interactions that are invisible to traditional linear sequencing methods. This capability is essential for driving discovery in genome biology, oncology, and therapeutic development. Arima Genomics occupies a unique niche in the life sciences market, acting as a critical partner for biopharmaceutical firms and academic institutions that require high-fidelity structural data to accelerate their research pipelines and improve clinical outcomes.
How much funding has Arima Genomics raised?
Arima Genomics has raised a total of $7.8M across 3 funding rounds:
Debt
$350K
Debt
$411K
Series B
$7M
Debt (2020): $350K with participation from PPP
Debt (2021): $411K led by PPP
Series B (2022): $7M supported by Tech Coast Angels, GENETRON HEALTH, Agile Technologies, Hiaqua Investments, and Ladder Ventures
Key Investors in Arima Genomics
GENETRON HEALTH
A leading precision oncology platform company specializing in cancer molecular profiling and advanced molecular biology data science.
Agile Technologies
A technology service firm focused on building durable business results through specialized consulting in technology and communications.
Ladder Ventures
A venture capital firm focused on supporting high-growth companies through strategic capital allocation and operational guidance.
What's next for Arima Genomics?
With the recent influx of capital, Arima Genomics is well-positioned to accelerate its product roadmap and expand its global footprint. The strategic focus will likely center on scaling the commercialization of its 3D genomics platform, enhancing data processing capabilities, and deepening partnerships within the precision oncology and biopharmaceutical sectors. As the industry shifts toward more comprehensive genomic insights, Arima Genomics is poised to capitalize on the increasing integration of structural biology into standard diagnostic and drug discovery workflows. Future growth will be driven by the continued adoption of its technology in large-scale clinical trials and the development of new applications that leverage the spatial organization of the genome to address unmet medical needs.
See full Arima Genomics company page
